2022

2021

2020

2019

2018

• 2022

  2022
  

  Mar 01, 2022

  Scrip Asks…What Does 2022 Hold For Biopharma? Part 4: Therapeutic Area Advances

  Chief Medical Officer, Steven O’Day, MD, discusses how Agenus’ next-generation CTLA-4 antibody could enhance the possibilities of immunotherapy.

• 2022
  

  Feb 17, 2022

  In a wily protein that helps cancer spread, researchers see a chance to make immunotherapy more effective

  Agenus featured in STAT News, where Agenus’ Head of Drug Discovery, Dhan Chand, PhD, discusses the importance and potential of TGF-beta in I-O, and Agenus’ anti-TGF-beta program AGEN1423.

• 2022
  

  Jan 25, 2022

  A new cancer immunotherapy brings cautious hope for a field long awaiting the next big breakthrough

  Agenus’ CEO, Garo H. Armen, and other industry leaders express their thoughts on what the future might hold for immunotherapies in cancer.

• 2022
  

  Jan 13, 2022

  Balstilimab With Zalifrelimab Elicits High, Durable Responses in Recurrent/Metastatic Cervical Cancer

  In patients with recurrent and/or metastatic cervical cancer, the second-line combination of balstilimab and zalifrelimab may offer meaningful clinical benefit, but further research is needed.

• 2021

  2021
  

  Nov 12, 2021

  Spurned by FDA on another immunotherapy, Agenus holds up early data for CTLA-4 drug across tumor types

  In a Phase I study across nine tumor types, Agenus’ CTLA-4 drug AGN1181 posted one complete response and three partial responses as a monotherapy, offering a key efficacy baseline as the biotech pursues a combination strategy with in-house PD-(L)1 drug balstilimab, according to data presented Friday at SITC.

• 2021
  

  Sep 19, 2021

  Balstilimab plus Zalifrelimab Displays Strong Efficacy, Survival Benefits in Recurrent/Metastatic Cervical Cancer

  The anti-PD-1 antibody balstilimab in combination with the anti-CTLA-4 antibody zalifrelimab (AGEN1884) exhibited impressive response rates, duration of response (DOR), and overall survival (OS) in patients with previously treated recurrent/metastatic cervical cancer, according to data from a single arm phase 2 trial (NCT03495882) presented at the 2021 ESMO Annual Congress.

• 2021
  

  Jul 20, 2021

  Big Pharma is betting billions on the next cancer breakthrough. Here are the 13 drug companies leading the way.

  Big Pharma is betting billions on a new class of cancer treatments. The hope is that the new approach will expand the benefits of immunotherapy to more patients. The first immunotherapies were approved a decade ago in 2011. These drugs, which harness the body’s own immune system to fight cancer, have delivered transformative benefits to some patients.

• 2021
  

  Jul 08, 2021

  Agenus to move California operations to new biomanufacturing cluster in Vacaville

  Lexington, MA-based Agenus has bought a 120-acre lot near the existing Genentech facility and plans to build its own facility of 400,000 square feet, the San Francisco Business Times reported Wednesday. It will help fill the void in the manufacturing space that was opened up when a Novartis facility shut down in 2015 and then a J&J plant in 2019.

• 2021
  

  Jul 08, 2021

  Agenus Sets Sights on New California Site Near Genetech

  Agenus an immuno-oncology company based out of Lexington, Mass., has purchased a 120-acre plot of land near Genentech’s manufacturing facility in Vacaville, Cali. The lot, which sold for $18 million by master-planned community builder A.G. Spanos, is expected to hold Agenus’ upcoming 400,000-sqaure foot facility.

• 2021
  

  May 18, 2021

  The growing TIGIT pipeline: Data Byte

  At least 17 therapeutic candidates targeting TIGIT are in preclinical and clinical testing for cancer, according to BioCentury’s BCIQ database…The TIGIT pipeline holds one bispecific molecule, preclinical candidate AGEN-1777 from Agenus.

• 2021
  

  May 18, 2021

  TIGIT fidgets lessen as Agenus’ mystery preclinical bispecific bags BMS pact worth up to $1.3B-plus

  The anti-TIGIT bispecific antibody AGEN-1777’s preclinical status didn’t stand in the way of Bristol Myers Squibb Co.’s whopper deal with Agenus Inc., which is collecting $200 million up front and as much as $1.36 billion in potential milestone payments in trade for development and commercial rights to the Fc-enhanced compound.

• 2021
  

  May 18, 2021

  Bristol Myers to pay up to $1.56 bln to develop, sell Agenus’s cancer therapy

  Drugmaker Bristol Myers Squibb (BMY.N) will pay biotech firm Agenus Inc (AGEN.O) up to $1.56 billion to exclusively develop and commercialize its experimental cancer drug, AGEN1777, the companies said on Tuesday.

• 2021
  

  May 18, 2021

  Bristol Pays Out $200m For Agenus' Preclinical Bispecific TIGIT

  Agenus president Jennifer Buell talked to Scrip about partnering with Bristol and the dual nature approach of AGEN1777.

• 2021
  

  May 18, 2021

  Bristol Myers writes $200M check for rights to Agenus checkpoint inhibitor

  Bristol Myers Squibb already has a cancer program targeting the TIGIT protein, but in acquiring rights to Agenus’s drug, the pharma giant adds a bispecific antibody that preclinical research suggests has the potential to be the best in this drug class.

• 2021
  

  May 18, 2021

  BMS sees potential first-in-class therapy in deal for Agenus’ bispecific TIGIT-targeting mAb

  BMS’s belief that Agenus has built a differentiated TIGIT-targeting bispecific molecule has resulted in a potentially transformative deal for the biotech, delivering $200 million up front for the preclinical program to fuel its further aspirations

• 2021
  

  May 18, 2021

  Bristol Myers pays Agenus $200M for drug aimed at top immunotherapy target

  Bristol Myers Squibb on Tuesday said it will pay $200 million to acquire rights to an experimental cancer immmunotherapy developed by Massachusetts biotech Agenus.

• 2021
  

  May 18, 2021

  BMS Makes Potential $1.56 Billion Commitment to Agenus' Antibody Program

  Bristol Myers Squibb Company and Agenus inked a licensing deal for Agenus’ proprietary bispecific antibody program, AGEN1777, and a second undisclosed target. AGEN1777 is an Fc-enhancement antibody Agenus is developing to target major inhibitory receptors found on T and NK cells that seem to improve anti-tumor activity.

• 2021
  

  May 18, 2021

  Bristol Myers Strikes $1.6 Billion Pact for New Cancer Drug

  Bristol Myers Squibb Co. has agreed to pay Agenus Inc. as much as $1.56 billion for the rights to a new kind of experimental drug that uses the body’s immune system to combat cancer.

• 2021
  

  May 18, 2021

  Bristol Myers Squibb pays $200M for Lexington biotech's cancer antibody

  Agenus Inc. has signed its largest licensing deal ever for a tumor-fighting antibody that is still in preclinical development.

• 2021
  

  May 18, 2021

  Lexington biotech licenses experimental cancer drug to Bristol Myers Squibb for $200m

  The Lexington-based biotech Agenus has licensed an experimental cancer-fighting drug to the pharmaceutical giant Bristol Myers Squibb for $200 million, the biotech’s largest licensing deal since it was founded in 1994.

• 2021
  

  May 18, 2021

  Bristol Myers bets big on anti-TIGIT bispecific from Agenus in a partnership worth $1.5B+

  Bristol Myers Squibb is enlisting a preclinical program from Agenus to its pipeline, plunking down $200 million upfront for a bispecific antibody that targets both TIGIT and another undisclosed target. The Big Pharma will sweeten the pot with up to $1.36 billion in potential milestones, and Agenus will retain options to develop the candidate in combination with some of its other programs.

• 2021
  

  May 18, 2021

  Bristol Myers hands over $200M upfront, $1.36B in biobucks for Agenus' preclinical TIGIT asset

  Bristol Myers Squibb, looking to the future beyond Opdivo, has penned a major biobucks pact an early-stage assets out of small biotech Agenus.

• 2021
  

  Apr 19, 2021

  FDA Approval Sought for Balstilimab for Recurrent or Metastatic Cervical Cancer

  A biologics license application (BLA) has been submitted to the FDA seeking the accelerated approval of balstilimab for use in the treatment of patients with recurrent or metastatic cervical cancer with disease progression on, or following, chemotherapy.

• 2021
  

  Apr 12, 2021

  AACR data suggest Agenus’ next-generation CTLA-4 blocker may expand responding patient group

  Agenus’ latest clinical data for AGEN1181

• 2020

  2020
  

  Dec 23, 2020

  Biomarkers — Improving Clinical Studies to Enhance Commercial Success for Biologics

  Drug developers want not only to find quantitative evidence that their therapies will work as designed, but also to anticipate which patient populations will respond positively to those regimens. Doing that could streamline clinical trials, accelerate approvals, and ultimately improve patient outcomes.

• 2019

  2019
  

  Oct 18, 2019

  UroGen Licenses Zalifrelimab From Agenus

  Agenus has granted UroGen Pharma Ltd. exclusive rights to develop and commercialize zalifrelimab (AGEN1884) via intravesical delivery in combination with UroGen’s UGN201 for urinary tract cancers.

• 2019
  

  Jun 07, 2019

  Agenus’ COO Speaks on the Next Level of Immuno-Oncology

  At an Education Session, Jennifer Buell, chief operating officer of Agenus, spoke on the trends and obstacles in immuno-oncology.

• 2019
  

  Apr 18, 2019

  Agenus scales the AI ALPS

  Agenus is using its artificial intelligence, machine learning platform to match cancer patients with the best monotherapy or combination therapy it has, and to uncover mechanisms of resistance to develop new therapies using non-responder data.

• 2019
  

  Apr 01, 2019

  Garo Armen And Audacity At Agenus

  What motivates a biopharma executive — a company founder, chair, CEO, or any other leader in the organization? In many industries and lines of business, where the sale of goods paves the simplest path to wealth, the prospect of great riches may be the only incentive needed.

• 2019
  

  Jan 30, 2019

  Finance Watch: Bitcoin For Biopharma? Agenus Gives BEST A Shot

  Investors in a February Biotech Electronic Security Token (BEST) offering will be able to put their money behind a single Agenus asset – the PD-1 inhibitor AGEN2034. Also, financial and strategic updates from Gossamer, Aduro, Novo's REPAIR Impact Fund and more.

• 2019
  

  Jan 29, 2019

  This Small Biotech Company Is Doing Its Own Digital Offering

  In a novel approach for the biotechnology industry, small-cap company Agenus Inc. is aiming to raise $50 million to $100 million by issuing digital securities backed by future sales of an experimental cancer drug.

• 2019
  

  Jan 29, 2019

  Agenus touts blockchain tech to roll out new ‘digital security’ for its PD-1, but will it work?

  Beset with setbacks, a once cash-poor Agenus had something to cheer late last year when behemoth Gilead signed on as a partner on up to five of its immuno-oncology programs. On Tuesday, the biotech offered investors an intriguing proposal: fund the development of a single drug, while preserving shareholder equity.

• 2019
  

  Jan 29, 2019

  Fintech And Biotech Are Coming Together To Transform Drug Development

  Today, fintech and biotech are coming together to create a new, targeted financing option that is intended to drive efficiencies and advantages in drug development.

• 2018

  2018
  

  Dec 20, 2018

  Lexington biotech Agenus signs drug development deal with Gilead

  Agenus has signed a deal with California-based Gilead Sciences that will pay the Lexington biotech $150 million to help develop and market up to five drugs to treat cancer by taking advantage of the body’s own immune system.

• 2018
  

  Dec 20, 2018

  Gilead Sciences Commits $150M to Agenus in Cancer Drug R&D Pact

  Xconomy San Francisco — For the second time this week, Gilead Sciences has partnered with a Boston-area biotech, this time with a deal that covers up to five experimental cancer immunotherapies being developed by Agenus.